{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:31:19Z","timestamp":1776259879519,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jaut.2021.102649","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T13:47:03Z","timestamp":1619876823000},"page":"102649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine"],"prefix":"10.1016","volume":"121","author":[{"given":"Haralampos M.","family":"Moutsopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2021.102649_bib1","series-title":"Immunology-Rheumatology in Questions","article-title":"Treatment and management of rheumatic diseases","author":"Moutsopoulos","year":"2021"},{"key":"10.1016\/j.jaut.2021.102649_bib2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1136\/annrheumdis-2018-213222","article-title":"Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomized clinical trial","volume":"77","author":"Park","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2021.102649_bib3","doi-asserted-by":"crossref","first-page":"104480","DOI":"10.1016\/j.jcv.2020.104480","article-title":"Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays","volume":"129","author":"Kohmer","year":"2020","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jaut.2021.102649_bib4","series-title":"COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases Developed by the ACR COVID-19 Vaccine Clinical Guidance Task Force","year":"2021"},{"key":"10.1016\/j.jaut.2021.102649_bib5","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","author":"Boyarsky","year":"2021","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jaut.2021.102649_bib6","article-title":"Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD","author":"Kennedy","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2021.102649_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","author":"Boyarsky","year":"2021","journal-title":"Annals of the Rheumatic Diseases Published Online First"},{"key":"10.1016\/j.jaut.2021.102649_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","author":"Cines","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2021.102649_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2009-03-206367","article-title":"\u03b22 Glycoprotein I (\u03b22GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome","volume":"115","author":"Sikara","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2021.102649_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/ard.2007.074476","article-title":"Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome","volume":"67","author":"Alpert","year":"2008","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841121000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841121000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:27:17Z","timestamp":1760257637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841121000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":10,"alternative-id":["S0896841121000573"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2021.102649","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A recommended paradigm for vaccination of rheumatic disease patients with the SARS-CoV-2 vaccine","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2021.102649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102649"}}